Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab ...

24 October 2026 · By · Wire by Fusion42

Published

24 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United Kingdom

◆ Source

Read at hmpgloballearningnetwork.com →

◆ Verified

Fusion42 · 24 October 2026 · Fusion42 review

The phase 3 VOLGA trial showed that perioperative durvalumab combined with enfortumab vedotin significantly improves event-free and overall survival in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin therapy, establishing this combination as a promising treatment option.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You can offer a new treatment route for bladder cancer patients who cannot take cisplatin, as this trial opens up a clear survival advantage with durvalumab plus enfortumab vedotin before surgery.

◆ Coverage

2 sources · 24 Oct 2026

◆ Related on Wire

◆ Topics

Biotechbladder-cancerimmunotherapyclinical-trialdurvalumabenfortumab-vedotin